ROCKWELL MEDICAL INC (RMTI) Stock Fundamental Analysis
USA - NASDAQ:RMTI - US7743743004 - Common Stock
1.16 USD
+0.01 (+0.87%)
1.15 USD
-0.01 (-0.86%)
RMTI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. The financial health of RMTI is average, but there are quite some concerns on its profitability. RMTI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
RMTI had negative earnings in the past year.
In the past year RMTI had a positive cash flow from operations.
In the past 5 years RMTI always reported negative net income.
RMTI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -3.99%, RMTI is doing good in the industry, outperforming 67.72% of the companies in the same industry.
RMTI has a Return On Equity of -6.90%. This is in the better half of the industry: RMTI outperforms 67.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.99% | ||
| ROE | -6.9% | ||
| ROIC | N/A |
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RMTI has a worse Gross Margin (17.52%) than 81.48% of its industry peers.
In the last couple of years the Gross Margin of RMTI has grown nicely.
RMTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 17.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
2. Health
2.1 Basic Checks
RMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
RMTI has more shares outstanding than it did 1 year ago.
RMTI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RMTI has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -7.52, we must say that RMTI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.52, RMTI is doing worse than 74.60% of the companies in the same industry.
The Debt to FCF ratio of RMTI is 3.93, which is a good value as it means it would take RMTI, 3.93 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of RMTI (3.93) is better than 82.01% of its industry peers.
A Debt/Equity ratio of 0.33 indicates that RMTI is not too dependend on debt financing.
RMTI's Debt to Equity ratio of 0.33 is in line compared to the rest of the industry. RMTI outperforms 49.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 3.93 | ||
| Altman-Z | -7.52 |
ROIC/WACCN/A
WACC8.19%
2.3 Liquidity
RMTI has a Current Ratio of 2.89. This indicates that RMTI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.89, RMTI is in line with its industry, outperforming 58.20% of the companies in the same industry.
RMTI has a Quick Ratio of 2.51. This indicates that RMTI is financially healthy and has no problem in meeting its short term obligations.
RMTI has a better Quick ratio (2.51) than 61.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 64.91% over the past year.
Looking at the last year, RMTI shows a decrease in Revenue. The Revenue has decreased by -6.79% in the last year.
Measured over the past years, RMTI shows a quite strong growth in Revenue. The Revenue has been growing by 10.61% on average per year.
EPS 1Y (TTM)64.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-655.56%
Revenue 1Y (TTM)-6.79%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-37.79%
3.2 Future
The Earnings Per Share is expected to decrease by -89.45% on average over the next years. This is quite bad
Based on estimates for the next years, RMTI will show a decrease in Revenue. The Revenue will decrease by -9.82% on average per year.
EPS Next Y-750%
EPS Next 2Y-151.28%
EPS Next 3Y-89.45%
EPS Next 5YN/A
Revenue Next Year-31.95%
Revenue Next 2Y-13.1%
Revenue Next 3Y-9.82%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RMTI. In the last year negative earnings were reported.
Also next year RMTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RMTI indicates a somewhat cheap valuation: RMTI is cheaper than 72.49% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, RMTI is valued cheaper than 93.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.88 | ||
| EV/EBITDA | 28.42 |
4.3 Compensation for Growth
RMTI's earnings are expected to decrease with -89.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-151.28%
EPS Next 3Y-89.45%
5. Dividend
5.1 Amount
No dividends for RMTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.16
+0.01 (+0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners17.19%
Inst Owner Change0.14%
Ins Owners4.38%
Ins Owner Change7.05%
Market Cap39.94M
Revenue(TTM)87.97M
Net Income(TTM)-2099000
Analysts82.5
Price Target4.08 (251.72%)
Short Float %3.7%
Short Ratio0.61
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.76%
Min EPS beat(2)1.96%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)53.92%
Min EPS beat(4)-198.04%
Max EPS beat(4)390.2%
EPS beat(8)6
Avg EPS beat(8)44.81%
EPS beat(12)9
Avg EPS beat(12)35.07%
EPS beat(16)12
Avg EPS beat(16)34.77%
Revenue beat(2)1
Avg Revenue beat(2)1.34%
Min Revenue beat(2)-3.53%
Max Revenue beat(2)6.2%
Revenue beat(4)3
Avg Revenue beat(4)2.42%
Min Revenue beat(4)-3.53%
Max Revenue beat(4)6.2%
Revenue beat(8)6
Avg Revenue beat(8)2.54%
Revenue beat(12)8
Avg Revenue beat(12)2.49%
Revenue beat(16)9
Avg Revenue beat(16)-0.35%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.18%
EPS NY rev (1m)0%
EPS NY rev (3m)14.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.45 | ||
| P/FCF | 14.88 | ||
| P/OCF | 11.42 | ||
| P/B | 1.31 | ||
| P/tB | 2.04 | ||
| EV/EBITDA | 28.42 |
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.08
FCFY6.72%
OCF(TTM)0.1
OCFY8.76%
SpS2.55
BVpS0.88
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.99% | ||
| ROE | -6.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 17.52% | ||
| FCFM | 3.05% |
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
F-Score6
Asset Turnover1.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 3.93 | ||
| Debt/EBITDA | 11.07 | ||
| Cap/Depr | 37.16% | ||
| Cap/Sales | 0.92% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 390.29% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | -7.52 |
F-Score6
WACC8.19%
ROIC/WACCN/A
Cap/Depr(3y)323.45%
Cap/Depr(5y)234.89%
Cap/Sales(3y)5.5%
Cap/Sales(5y)3.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-655.56%
EPS Next Y-750%
EPS Next 2Y-151.28%
EPS Next 3Y-89.45%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.79%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-37.79%
Revenue Next Year-31.95%
Revenue Next 2Y-13.1%
Revenue Next 3Y-9.82%
Revenue Next 5YN/A
EBIT growth 1Y58.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-161.54%
EBIT Next 3Y-29.69%
EBIT Next 5YN/A
FCF growth 1Y134.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y147.84%
OCF growth 3YN/A
OCF growth 5YN/A
ROCKWELL MEDICAL INC / RMTI FAQ
What is the ChartMill fundamental rating of ROCKWELL MEDICAL INC (RMTI) stock?
ChartMill assigns a fundamental rating of 3 / 10 to RMTI.
What is the valuation status for RMTI stock?
ChartMill assigns a valuation rating of 2 / 10 to ROCKWELL MEDICAL INC (RMTI). This can be considered as Overvalued.
How profitable is ROCKWELL MEDICAL INC (RMTI) stock?
ROCKWELL MEDICAL INC (RMTI) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for RMTI stock?
The Earnings per Share (EPS) of ROCKWELL MEDICAL INC (RMTI) is expected to decline by -750% in the next year.